株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

視神経脊髄炎 (デビック病):パイプライン製品の分析

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 293889
出版日 ページ情報 英文 146 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
視神経脊髄炎 (デビック病):パイプライン製品の分析 Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2019
出版日: 2019年11月25日 ページ情報: 英文 146 Pages
概要

デビック病としても知られる視神経脊髄炎 (NMO) は、脳、脊髄、神経の疾患あるいは損傷によって引き起こされる珍しい神経障害であり、自身の免疫系が異常反応し、体内の細胞や組織を攻撃してしまう自己免疫疾患です。免疫系が髄鞘を攻撃する事例もあります。症状としては、失明、脱力感、麻痺、腸および膀胱の問題などがあります。

当レポートでは、世界における視神経脊髄炎治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

イントロダクション

  • 調査範囲

視神経脊髄炎 (デビック病) の概要

治療薬の開発

  • パイプライン製品の概要
  • 開発中の治療薬:企業別
  • 開発中の治療薬:大学・研究機関別
  • 開発中の製品:企業別
  • 開発中の製品:大学・研究機関別

視神経脊髄炎:治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

視神経脊髄炎:治療薬開発に従事している企業

  • 2-BBB Medicines BV
  • Alexion Pharmaceuticals Inc
  • Apellis Pharmaceuticals Inc
  • Biogen Inc
  • Bionure Farma SL
  • 中外製薬
  • Clene Nanomedicine Inc
  • HanAll Biopharma Co Ltd
  • Karus Therapeutics Ltd
  • LFB SA
  • Marathon Pharmaceuticals LLC
  • MedImmune LLC
  • Opexa Therapeutics Inc
  • Shire Plc

薬剤プロファイル

視神経脊髄炎:休止中のプロジェクト

視神経脊髄炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Table 1: Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 4: Products under Development by Companies, H2 2019
  • Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 6: Products under Development by Universities/Institutes, H2 2019
  • Table 7: Number of Products by Stage and Target, H2 2019
  • Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 9: Number of Products by Stage and Route of Administration, H2 2019
  • Table 10: Number of Products by Stage and Molecule Type, H2 2019
  • Table 11: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Accendatech Au Pty Ltd, H2 2019
  • Table 12: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Ahead Therapeutics SL, H2 2019
  • Table 13: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2019
  • Table 14: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Apsara Therapeutics, H2 2019
  • Table 15: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bio-Thera Solutions Ltd, H2 2019
  • Table 16: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Biogen Inc, H2 2019
  • Table 17: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bionure Farma SL, H2 2019
  • Table 18: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Boston Pharmaceuticals Inc, H2 2019
  • Table 19: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chord Therapeutics Sarl, H2 2019
  • Table 20: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
  • Table 21: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Cour Pharmaceuticals Development Co Inc, H2 2019
  • Table 22: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Endece LLC, H2 2019
  • Table 23: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by EnhanX Biopharm Inc, H2 2019
  • Table 24: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Ferring International Center SA, H2 2019
  • Table 25: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by H. Lundbeck AS, H2 2019
  • Table 26: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by HanAll Biopharma Co Ltd, H2 2019
  • Table 27: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by ImCyse SA, H2 2019
  • Table 28: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Imstem Biotechnology Inc, H2 2019
  • Table 29: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by LFB SA, H2 2019
  • Table 30: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019
  • Table 31: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by NovelMed Therapeutics Inc, H2 2019
  • Table 32: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Orion BioScience Inc, H2 2019
  • Table 33: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Thelial Technologies SA, H2 2019
  • Table 34: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Tolerion Inc, H2 2019
  • Table 35: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Viela Bio Inc, H2 2019
  • Table 36: Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Yantai RC-Pharmaceutical Co Ltd, H2 2019
  • Table 37: Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects, H2 2019
  • Table 38: Neuromyelitis Optica (Devic's Syndrome) - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
目次
Product Code: GMDHC11529IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica - Pipeline Review, H2 2019, provides an overview of the Neuromyelitis Optica (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person's immune system (the body's natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 1, 6, 12, 3 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Neuromyelitis Optica (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuromyelitis Optica (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuromyelitis Optica (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neuromyelitis Optica (Devic's Syndrome) - Overview
  • Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics Development
    • Accendatech Au Pty Ltd
    • Ahead Therapeutics SL
    • Alexion Pharmaceuticals Inc
    • Apsara Therapeutics
    • Bio-Thera Solutions Ltd
    • Biogen Inc
    • Bionure Farma SL
    • Boston Pharmaceuticals Inc
    • Chord Therapeutics Sarl
    • Chugai Pharmaceutical Co Ltd
    • Cour Pharmaceuticals Development Co Inc
    • Endece LLC
    • EnhanX Biopharm Inc
    • Ferring International Center SA
    • H. Lundbeck AS
    • HanAll Biopharma Co Ltd
    • ImCyse SA
    • Imstem Biotechnology Inc
    • LFB SA
    • Mitsubishi Tanabe Pharma Corp
    • NovelMed Therapeutics Inc
    • Orion BioScience Inc
    • Thelial Technologies SA
    • Tolerion Inc
    • Viela Bio Inc
    • Yantai RC-Pharmaceutical Co Ltd
  • Neuromyelitis Optica (Devic's Syndrome) - Drug Profiles
    • ABX-1431 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACT-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-1511 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAT-4406 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • batoclimab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BN-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BOS-172767 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cladribine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-15107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENX-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Target CD19 and CD20 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMS-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMS-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inebilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit C3 and C5 for Neuromyelitis Optica - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MT-3921 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NDC-1308 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • olamkicept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORNx-KI - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ravulizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzyme to Inhibit IgG for Neuromyelitis Optica - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide for Neuromyelitis Optica - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • satralizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Neuromyelitis Optica - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • telitacicept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • The-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOL-3052 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ublituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects
  • Neuromyelitis Optica (Devic's Syndrome) - Discontinued Products
  • Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 01, 2019: FDA and EMA agree to review Roche's satralizumab applications
      • Sep 12, 2019: Roche's drug mitigates relapse risk in late-stage study for NMOSD
      • Sep 09, 2019: Viela Bio announces data presentations at the 35th Congress of the European Committee for treatment and research in Multiple Sclerosis
      • Sep 06, 2019: Viela Bio announces publication in The Lancet of pivotal study results of Inebilizumab in patients with Neuromyelitis Optica Spectrum Disorder
      • Sep 04, 2019: Genentech to present pivotal data for Satralizumab in Neuromyelitis Optica Spectrum Disorder at ECTRIMS
      • Sep 04, 2019: Roche to present data for satralizumab in neuromyelitis optica spectrum disorder at ECTRIMS
      • Aug 28, 2019: Alexion announces upcoming data presentations at 35th Congress of the European Committee for treatment and research in Multiple Sclerosis
      • Aug 27, 2019: European Commission approves SOLIRIS (eculizumab) for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
      • Aug 27, 2019: Viela Bio announces U.S. FDA accepts for review Inebilizumab biologics license application for neuromyelitis Optica spectrum disorder
      • Jul 26, 2019: Alexion receives positive CHMP Opinion for SOLIRIS (Eculizumab) for the treatment Of NMOSD
      • Jun 28, 2019: FDA approves Alexion's Soliris as first treatment for CNS disease NMOSD
      • May 07, 2019: Viela Bio presents pivotal study results of Inebilizumab in patients with neuromyelitis optica spectrum isorder in a plenary session at the American Academy of Neurology Annual Meeting
      • May 03, 2019: New England Journal Of Medicine publishes positive phase 3 PREVENT data for SOLIRIS (Eculizumab) in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
      • Apr 29, 2019: Genentech to present on Satralizumab at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
      • Apr 18, 2019: Viela Bio receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for treatment of Neuromyelitis Optica Spectrum Disorder
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer
Back to Top